Shuttle Pharmaceuticals Holdings, Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Forvis Mazars LLP (Atlanta) issued a consent letter on October 21, 2026, confirming agreement with Item 4.01 statements in Shuttle's October 16, 2026 Form 8-K. The letter does not disclose the specific contents of Item 4.01 (typically auditor changes, dismissals, or disputes), stating only agreement with 'statements contained therein with respect to our firm' and declining to opine on other registrant statements. The actual material event is not detailed in this exhibit.
Why this rating
Auditor consent letter is routine disclosure; material event (likely auditor change) is unspecified. Cannot assess impact without Item 4.01 content.
Extracted items
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.